Relay Therapeutics, Inc. (RLAY)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$205.9M
Cash & Equivalents
$51.1M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$2,765M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI... PHASE3 Recruiting 540
NCT07584226 A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors PHASE1 Recruiting 35

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for RLAY.

SEC EDGAR Filings

All SEC filings for Relay Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.